Vaccinex, INC Form 4 insider transactions

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., has increased his holdings through the acquisition of common stock and the exercise of pre-funded warrants.

Vaccinex CEO Maurice Zauderer and Vaccinex (Rochester), L.L.C. reported transactions involving the acquisition of common stock and holdings of derivative securities.

CEO Maurice Zauderer and Vaccinex (Rochester), L.L.C. report changes in beneficial ownership of Vaccinex, Inc. stock and warrants following warrant exercise price adjustments.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., reports adjustments to warrant exercise prices and acquisition of shares through warrant exercises and inducement agreements.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., reports acquiring 100 shares of common stock at $4.51 per share on August 9, 2024, and discloses beneficial ownership through related entities.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., along with FCMI Parent Co., reported changes in beneficial ownership of the company's common stock and warrants.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., reports purchasing shares and holding warrants both directly and indirectly through related entities.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., reports acquiring a substantial number of shares through multiple transactions, along with indirect ownership through related entities.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., has increased his beneficial ownership through recent stock purchases.

Ernest S. Smith, SVP of Research & CSO at Vaccinex, Inc., files an amended Form 4 to correct the transaction date and exercise price of a stock option grant.

Jill Sanchez, CFO of Vaccinex, files an amendment to a previous SEC Form 4 to correct the transaction date and exercise price of a stock option grant.

Elizabeth Evans, COO of Vaccinex, files an amended SEC Form 4/A to correct the transaction date and exercise price of a stock option grant.

Maurice Zauderer, CEO of Vaccinex, files an amended SEC Form 4 to correct the transaction date, exercise price, and expiration date of a stock option grant.

Director Barbara Yanni reports the acquisition of stock options in Vaccinex, Inc.

Director Gerald E. Van Strydonck acquired common stock and stock options in Vaccinex, Inc. on May 10, 2024, according to a Form 4 filing.

Director Bala S. Manian acquired options to purchase Vaccinex, Inc. common stock in lieu of cash compensation and as part of the company's 2018 Omnibus Incentive Plan.

Director Chrystyna Bedrij-Stecyk reports the acquisition of 10,108 stock options in Vaccinex, Inc.

Director Jacob Frieberg reports stock option grants and adjustments following a reverse stock split at Vaccinex, Inc.

Albert Friedberg, a director and 10% owner of VaccinEx, Inc., reported a transaction involving the acquisition of common stock and holdings of derivative securities.

Vaccinex CEO Maurice Zauderer reports the acquisition of common stock and warrants, along with adjustments to existing holdings, as detailed in a recent SEC filing.

Albert Friedberg, a director and 10% owner of Vaccinex, Inc., reports the acquisition of shares and warrants, along with adjustments due to a reverse stock split.

Elizabeth Evans, Chief Operating Officer of Vaccinex, Inc., reports the acquisition of stock options.

Ernest S. Smith, SVP, Research & CSO of Vaccinex, Inc., reports the acquisition of 1,341 stock options on March 20, 2024.

Jill Sanchez, CFO of Vaccinex, Inc., reports the acquisition of stock options.

Vaccinex CEO Maurice Zauderer reports transactions involving common stock and derivative securities, including stock options and warrants.